Overview

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Status:
Completed
Trial end date:
2000-05-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Bone marrow that has been treated to remove certain white blood cells may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy, and may reduce the chance of developing graft-versus-host disease following bone marrow transplantation. PURPOSE: Phase IV trial to study the incidence of graft-versus-host disease in patients who have hematologic cancer and who are undergoing bone marrow transplantation from a donor.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Maryland
University of Maryland, Baltimore
Collaborator:
University of Maryland Greenebaum Cancer Center
Treatments:
Antilymphocyte Serum
Cyclophosphamide
Thiotepa
Criteria
DISEASE CHARACTERISTICS: Histologically proven malignancy or condition of the following
types: Acute myelogenous leukemia (not M5 or M6) or lymphocytic leukemia in first or
greater remission or early relapse OR Chronic myelogenous leukemia OR Myelodysplastic
syndrome OR Aggressive or refractory non-Hodgkin's lymphoma OR Aggressive or refractory
Hodgkin's disease OR Multiple myeloma at early relapse or after conventional chemotherapy
to reduce tumor mass OR High risk chronic lymphocytic leukemia OR Aplastic anemia
HLA-matched or 1 antigen mismatched (related or unrelated) available as donor

PATIENT CHARACTERISTICS: Age: 50 and under Performance status: Karnofsky 70-100% Life
expectancy: Greater than 8 weeks Hematopoietic: Not specified Hepatic: Bilirubin less than
2 mg/dL SGOT less than 4 times upper limit of normal (ULN) Renal: Creatinine less than 2
times ULN OR Creatinine clearance greater than 60 mL/min Cardiovascular: LVEF at least 50%
by MUGA Pulmonary: DLCO at least 50% Other: HIV negative No active extramedullary disease
Not pregnant or nursing Negative pregnancy test Fertile patients must use effective
contraception

PRIOR CONCURRENT THERAPY: See Disease Characteristics